Location on site: Resources section
1. Introduction
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease in dogs, particularly affecting small- to medium-sized breeds such as Cavalier King Charles Spaniels, Dachshunds, Miniature Poodles, and Chihuahuas. Given its high prevalence and progressive nature, MMVD represents a major focus of small animal cardiology and an area where standardized, evidence-based guidance is essential.
The American College of Veterinary Internal Medicine (ACVIM) consensus guidelines provide that framework. Developed by leading veterinary cardiologists, the ACVIM guidelines aim to translate the growing body of scientific evidence into clear, practical recommendations for everyday clinical use. The most recent and widely implemented version is the 2019 ACVIM Consensus Statement on the Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs, which refined disease staging, clarified diagnostic thresholds, and strengthened treatment recommendations based on high-quality clinical trials.
These guidelines matter because MMVD management decisions—particularly the timing of intervention—directly affect patient longevity and quality of life. Prior to standardized staging, variation in diagnostic criteria and treatment initiation led to inconsistent care. The ACVIM framework promotes uniform language, reproducible diagnostic benchmarks, and stage-appropriate therapy, allowing general practitioners, cardiology specialists, and referral centers to align their clinical decision-making. This article provides a practical, stage-by-stage summary of the ACVIM MMVD guidelines, with an emphasis on actionable steps for veterinary practice.
2. Background and Purpose
The ACVIM MMVD guidelines were developed in response to decades of evolving research into the pathophysiology, diagnosis, and treatment of degenerative mitral valve disease. Earlier approaches relied heavily on auscultation and clinical signs, often delaying intervention until congestive heart failure (CHF) developed. Advances in diagnostic imaging—particularly echocardiography and standardized radiographic measurements—created the need for unified thresholds that could be applied consistently across practices.
To address this, the ACVIM convened an international expert panel composed of board-certified veterinary cardiologists and internists with extensive clinical and research experience in MMVD. Panel members reviewed available literature, including randomized controlled trials, observational studies, and meta-analyses. Recommendations were graded based on strength of evidence, with particular emphasis on landmark studies such as the EPIC trial, which demonstrated a survival benefit for preclinical treatment in dogs with significant cardiomegaly.
The purpose of the guidelines is threefold:
- Standardize disease staging using objective criteria.
- Define evidence-based treatment recommendations for each stage.
- Improve patient outcomes by identifying the optimal timing for intervention.
Compared with earlier versions, the 2019 consensus statement introduced clearer definitions for Stage B2 disease, emphasized the use of normalized echocardiographic measurements, and reinforced the importance of combining imaging modalities rather than relying on a single parameter. These updates reflect both new evidence and a shift toward more proactive management of MMVD before the onset of CHF.
3. Stage-by-Stage Summary
The ACVIM guidelines divide MMVD into five stages (A–D), reflecting disease progression from risk only to refractory heart failure. Below is a practical, actionable summary of each stage.
Stage A
WHO: At-risk breeds without disease EXAM FINDINGS: No murmur, normal cardiac exam DIAGNOSTICS: Optional baseline echo/radiographs TREATMENT: None MONITORING: Annual cardiac assessment VHS/VLAS: Establish baseline values
Clinical context:
Stage A dogs are predisposed to MMVD based on breed or familial history but have no current structural heart disease. Common examples include young Cavalier King Charles Spaniels with no audible murmur.
Practice tips:
- Emphasize preventive care and education rather than diagnostics.
- Baseline imaging may be helpful in breeding animals or highly predisposed breeds.
- Avoid unnecessary medications; no evidence supports prophylactic treatment.
Stage B1
WHO: Murmur present, minimal heart enlargement EXAM FINDINGS: Systolic murmur, no CHF signs DIAGNOSTICS: Echo and/or radiographs CRITERIA: VHS <10.5, VLAS <2.5, LA:Ao <1.6, LVIDdN <1.7 TREATMENT: None currently indicated MONITORING: Every 6-12 months CLIENT EDUCATION: Watch for CHF signs
Clinical context:
Stage B1 represents dogs with confirmed MMVD and a systolic murmur but without clinically significant cardiac remodeling. These patients are asymptomatic and do not meet criteria for cardiomegaly.
Practice tips:
- Echocardiography is the gold standard for staging but high-quality radiographs may be sufficient initially.
- Do not initiate pimobendan or ACE inhibitors at this stage.
- Educate owners about early signs of CHF, including cough, tachypnea, and exercise intolerance.
Stage B2
WHO: Significant cardiomegaly, no CHF signs EXAM FINDINGS: Murmur ≥III/VI DIAGNOSTICS: Echo and/or radiographs RADIOGRAPHIC CRITERIA: VHS ≥11.5 OR VLAS ≥3.0 ECHO CRITERIA: LA:Ao ≥1.6 AND LVIDdN ≥1.7 TREATMENT: Pimobendan 0.25-0.3 mg/kg q12h MONITORING: Every 4-6 months HOME MONITORING: Resting respiratory rate
Clinical context:
Stage B2 is a critical intervention point. Dogs have significant left-sided cardiac enlargement but remain asymptomatic. Evidence shows that early pimobendan therapy delays the onset of CHF and extends survival.
Practice tips:
- Confirm cardiomegaly using objective measurements; avoid subjective interpretation alone.
- Pimobendan is the only medication with strong evidence at this stage.
- Encourage owners to track resting respiratory rate (RRR) at home to detect early CHF.
Stage C
WHO: Current/past CHF EXAM FINDINGS: Pulmonary edema, respiratory signs TREATMENT:
- Pimobendan 0.25-0.3 mg/kg q12h
- Furosemide 2-4 mg/kg q8-12h (adjust as needed)
- ACE inhibitor 0.5 mg/kg q12-24h
- Spironolactone 0.5-2 mg/kg q12-24h MONITORING: Frequent, adjust to patient DIET: Moderate sodium restriction
Clinical context:
Stage C includes dogs with active or previously resolved CHF. Management focuses on relieving congestion, maintaining cardiac output, and minimizing adverse effects.
Practice tips:
- Individualize diuretic dosing based on clinical response and renal values.
- Recheck frequently after diagnosis or medication changes.
- Dietary sodium moderation supports medical therapy but should not compromise appetite.
Stage D
WHO: Refractory heart failure TREATMENT: Maximized medical therapy ADDITIONAL: Consider torasemide, sildenafil PROGNOSIS: Guarded REFERRAL: Strongly recommended
Clinical context:
Stage D dogs have CHF that is poorly responsive to standard therapy. These cases are challenging and often require advanced diagnostics and off-label treatments.
Practice tips:
- Referral to a cardiologist is strongly advised.
- Quality-of-life discussions with owners are essential.
- Expect narrow therapeutic margins and frequent reassessment.
4. Diagnostic Thresholds Quick Reference
Accurate staging depends on objective, reproducible measurements. The ACVIM guidelines emphasize combining radiographic and echocardiographic criteria whenever possible.
- Vertebral Heart Score (VHS): ≥11.5 (breed-adjusted where applicable)
- Vertebral Left Atrial Size (VLAS): ≥3.0
- Left Atrium to Aorta Ratio (LA:Ao): ≥1.6
- Normalized Left Ventricular Internal Diameter in Diastole (LVIDdN): ≥1.7
Radiographs vs. echocardiography:
- Radiographs are widely available and useful for screening and monitoring pulmonary edema.
- Echocardiography provides definitive structural assessment and is preferred for staging B2 disease.
Combining measurements:
No single parameter should be used in isolation. Concordance between VHS/VLAS and echo measurements strengthens staging confidence and reduces misclassification.
5. Treatment Algorithm Flowchart (Descriptive)
The ACVIM MMVD treatment algorithm can be visualized as a decision tree:
- Murmur detected on auscultation
- → Perform imaging (radiographs ± echocardiography)
- → Assess for cardiomegaly
- No enlargement → Stage B1 → Monitor
- Significant enlargement → Stage B2 → Start pimobendan
- → Monitor for CHF signs
- CHF present → Stage C → Initiate combination therapy
- Refractory CHF → Stage D → Escalate therapy and refer
This flowchart reinforces timely intervention and minimizes unnecessary treatment.
6. Monitoring Recommendations
Ongoing monitoring is essential across all MMVD stages and should be tailored to disease severity.
Home monitoring:
- Resting respiratory rate (RRR) measured during sleep
- Persistent RRR >30–35 breaths/min warrants reassessment
Recheck intervals:
- Stage A: Annually
- Stage B1: Every 6–12 months
- Stage B2: Every 4–6 months
- Stage C/D: Every 1–3 months or as clinically indicated
Early reassessment triggers:
- Increased cough or respiratory effort
- Exercise intolerance
- Syncope or weakness
- Rising RRR trends
Early detection of progression allows timely therapy adjustment and improves outcomes.
7. Key Updates from Previous Guidelines
The 2019 ACVIM MMVD guidelines introduced several important changes:
- Clearer definition of Stage B2, supported by EPIC trial data
- Stronger recommendation for pimobendan in asymptomatic dogs with cardiomegaly
- Greater emphasis on normalized echocardiographic measurements
- Encouragement to combine diagnostic modalities
These updates shifted MMVD management toward earlier, evidence-based intervention, with practical implications for both general practitioners and specialists. The result is more consistent care, improved survival times, and better quality of life for dogs with MMVD.
This practical summary is intended to support, not replace, clinical judgment and individualized patient care in accordance with the ACVIM consensus guidelines.
Related Resources
- MMVD in Dogs: Complete Guide — In-depth guide to myxomatous mitral valve disease in dogs.
- Signs of Heart Disease in Dogs — Learn to recognize early warning signs of cardiac disease.